Press release
Global Pharmacogenomics Market, by Technology Type (Polymerase Chain Reaction, Sequencing, Microarray, and Other Technologies), and by Application (Drug Discovery and Therapeutic Application) and by Geography - Trends and Forecast to 2025
Major factors that propel the market are increasing demand for personalized drugs, increasing prevalence of several non-infectious and infectious diseases, rising utilization of these technology for effective treatment therapeutics, and growing awareness about benefits associated with pharmacogenomics. Continuous collaboration among pharmacogenomics manufacturers for various applications in clinical and translational research is also expected to drive growth of the market across regions. In 2016, Merck & Co. Inc., collaborated with Biocartis, an innovative molecular diagnostic company to develop and commercialize a new liquid biopsy technology for RAS biomarker testing.
Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1053
The global pharmacogenomics market was valued at US$ 7,623.9 million in 2016 and is expected to witness a CAGR of 7.6% during the forecast period (2017 – 2025).
This report provides in-depth analysis of pharmacogenomics and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2016 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, regulatory scenario, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global pharmacogenomics market based on the following parameters – company overview, financial performance, geographical presence, key developments and strategies, and future plans
Key companies covered as a part of this study include Thermo Fisher Scientific Inc., Bayer AG, AstraZeneca plc, Assurex Health, GE Healthcare, Bristol-Myers Squibb Company, Qiagen, Inc., F. Hoffmann-La Roche Ltd, Transgenomic, Inc., Abbott Laboratories, Inc., and GlaxoSmithKline
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future type up-gradation, market expansion, and marketing tactics
The global pharmacogenomics market report caters to various stakeholders in this industry including investors, researchers, pharmacogenomics manufacturers, new entrants, and financial analysts.
Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the pharmacogenomics market.
Complete Report Details @ https://www.coherentmarketinsights.com/press-release/pharmacogenomics-market-to-surge-past-us-146-billion-by-2025-468
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit our news Website: http://www.coherentchronicle.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Pharmacogenomics Market, by Technology Type (Polymerase Chain Reaction, Sequencing, Microarray, and Other Technologies), and by Application (Drug Discovery and Therapeutic Application) and by Geography - Trends and Forecast to 2025 here
News-ID: 950837 • Views: …
More Releases from CMI - Research
Global Generic Sterile Injectable Market - Insights, Size, Share, Opportunity An …
The generic sterile injectable market is expected to gain steady traction in the foreseeable future as the sterile injectable products find its application across a wide number of diseases and medical condition. Manufacturers are focused on increasing the production of generic sterile injectable to meet the rising demands without compromising on the quality of the injectable.
Apart from prevalence of chronic diseases, several other factors that are responsible to fuel the…
Global Intravenous Access Devices Market - Catheters (Midline Peripheral Cathete …
Rising incidence of cardiovascular disease due to increase in the prevalence of diabetes, high blood pressure cases and number of smokers worldwide is expected to favor the demand for intravenous access device around the globe.
According to World Health Organization (WHO), in 2015 around 17.7 million people died due to cardiovascular disease worldwide. Furthermore, the majority of deaths are occurred in emerging economies due to high prevalence rate and lack of…
Global Myelodysplastic Syndrome (MDS) Treatment Market, By Drug (Azacitidine, Le …
According to the American Society of Hematology, in 2016, prevalence of MDS ranged from 0.22-13.2 per 100,000, on all age categories and ethnicities globally. Increasing public awareness about the disease and introduction of new treatment for MDS will drive the growth of the market. Furthermore, growing aging population is analyzed to be a major factor propelling the growth of myelodysplastic syndrome treatment market. According to NCBI, 2012, the incidence of…
Global Multiplexed Diagnostic Market by Product Type Reagents & Consumables and …
The multiplexed diagnostic market is gaining significant traction due to the rising prevalence of autoimmune diseases. According to the Centers for Disease Control and Prevention (CDC), the prevalence of arthritis from 2013 to 2015, was estimated in 54 million U.S adults (22.7%) and by 2040, it is expected to be 78 million (26%) U.S adults age 18 years or older. The data represent the high prevalence of autoimmune diseases, indicating…
More Releases for Pharmacogenomics
Pharmacogenomics - Top Companies Regional and Data Analysis
Pharmacogenomics is a branch of science, which studies the role of gene over the activity of a drugs and hence helps the refreshers in predicting the response of novel as well as previously available therapies.
Get More Details with Sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00007564/?utm_source=OpenPR&utm_medium=10129
Major Companies operating in the Pharmacogenomics Market are:
• F. Hoffmann-la Roche Ltd
• Abbott
• Oxford Nanopore Technologies
• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• QIAGEN
• Agilent Technologies, Inc.
• Myriad Genetics, Inc.
• Admera Health
Contact Us:
If you have any queries about…
Pharmacogenomics Market worth $5.8 billion by 2028
North America region is witnessing increasing investments and research activities in the field of drug discovery and development. The need for advanced therapies due to rising rate of cancer has contributed to growth of the pharmacogenomics market.
Pharmacogenomics Market [https://www.marketsandmarkets.com/Market-Reports/pharmacogenomics-market-142682251.html?utm_source=ABnewswire&utm_campaign=Paid&utm_content=Referral] in terms of revenue was estimated to be worth $3.5 billion in 2023 and is poised to reach $5.8 billion by 2028, growing at a CAGR of 10.6% from 2023 to…
Genetic Medicine: Unveiling the Power of Pharmacogenomics
Based on technology, the pharmacogenomics market is segmented into PCR, sequencing, microarray, gel electrophoresis, mass spectrometry, and others. The market for the PCR segment is subsegmented into real time PCR, standard PCR, and digital PCR. The PCR segment dominated the pharmacogenomics market in 2021 and is expected to register the highest CAGR during the forecast period.
Download Sample PDF Details at: https://www.theinsightpartners.com/sample/TIPRE00007564?utm_source=OpenPR&utm_medium=10776
The pharmacogenomics market is segmented on the basis of…
Complete PDF Guide On Pharmacogenomics [PDF]
According to our latest study on "Pharmacogenoics Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Technology, Application, and End User," the market is projected to reach US$ 14,107.80 million by 2028 from US$ 7,087.81 million in 2021; it is expected to grow at a CAGR of 10.3% from 2021 to 2028. The report highlights the key factors driving the market growth and prominent players with their…
Global Pharmacogenomics Market Size & Trends
According to a new market research report published by Global Market Estimates, the global pharmacogenomics market is projected to grow at a CAGR of 9.6% from 2023 to 2028.
The growth of the global pharmacogenomics market is driven by advancements in genomics and DNA sequencing technologies, the rising demand for personalized medicine, regulatory support from agencies like the FDA, cost-effectiveness through reduced adverse reactions, and a growing aging population with complex…
Global Pharmacogenomics Services Market Insights | 2022-2032
The Pharmacogenomics Services Market refers to the services provided by companies and laboratories that offer personalized medicine based on a patient's genetic makeup. Pharmacogenomics is the study of how an individual's genes affect their response to certain drugs, and the pharmacogenomics services market focuses on utilizing this knowledge to optimize drug therapy.
These services typically involve genetic testing to identify specific genetic variations that may impact a patient's response to certain…
